Posted by Michael Wonder on 11 Dec 2017
NICE U-turn backs combo for kidney cancer
11 December 2017 - In a turnaround from its earlier position, the NICE is now endorsing NHS funding for Eisai’s Kisplyx when used in combination with everolimus for kidney cancer.
The combination is being recommended as an option for treating advanced renal cell carcinoma in adults who have had one previous treatment with vascular endothelial growth factor-targeted therapy - but only if the patient’s Eastern Cooperative Oncology Group performance status score is 0 or 1 and the company provides Kisplyx (lenvatinib) with the discount agreed in the patient access scheme.
In earlier draft recommendations, NICE’s committee had concluded that there were uncertainties in the clinical evidence for Kisplyx plus everolimus (Novartis’ Afinitor) and that the combination was not cost effective.
